Novartis Ag Adr (NVS)

Nov 14, 2024

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - GlobeNewswire Inc.

Nov 14, 2024

Nov 06, 2024

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance

Nov 06, 2024

Nov 01, 2024

Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis

Nov 01, 2024

Oct 29, 2024

Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar

Oct 29, 2024

Oct 29, 2024

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart

Oct 29, 2024

Oct 29, 2024

Chemical Biology in Biomedical Research - Novartis

Oct 29, 2024

Oct 29, 2024

Radioligand therapy: delivering now, building for the future - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis at ASH - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis 2022 Financial Results - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis Financial Results – Q2 2023 - Novartis

Oct 29, 2024

Oct 29, 2024

Translational medicine research at Novartis - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis Financial Results – Q2 2024 - Novartis

Oct 29, 2024

Oct 29, 2024

Inclusivity - Novartis

Oct 29, 2024

Oct 29, 2024

Collaborations - Novartis

Oct 29, 2024

Oct 25, 2024

Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.

Oct 25, 2024

Oct 23, 2024

South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research

Oct 23, 2024

Oct 22, 2024

5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart

Oct 22, 2024

Oct 18, 2024

21 Best Healthcare Companies to Invest In - Morningstar

Oct 18, 2024

Oct 17, 2024

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise

Oct 17, 2024

Oct 16, 2024

Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.

Oct 16, 2024

Oct 15, 2024

Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.

Oct 15, 2024

Oct 14, 2024

Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart

Oct 14, 2024

Oct 11, 2024

Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 11, 2024

Oct 09, 2024

Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

Oct 09, 2024

Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

Oct 07, 2024

Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine

Oct 07, 2024

Oct 01, 2024

NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com

Oct 01, 2024

Sep 25, 2024

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar

Sep 25, 2024

Sep 21, 2024

Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 21, 2024

Sep 20, 2024

Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research

Sep 20, 2024

Sep 18, 2024

Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart

Sep 18, 2024

Sep 17, 2024

Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart

Sep 17, 2024

Sep 17, 2024

North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research

Sep 17, 2024

Sep 16, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Sep 16, 2024

Sep 12, 2024

Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News

Sep 12, 2024

Sep 11, 2024

Novartis lower as BofA downgrades on risks to valuation - MSN

Sep 11, 2024

Sep 09, 2024

Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.

Sep 09, 2024

Sep 05, 2024

Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca

Sep 05, 2024

Sep 04, 2024

Spain Congestive Heart Failure Drugs Market Size & Outlook, 2030 - Grand View Research

Sep 04, 2024